Dr. Reddy's Laboratories Stock (NYSE:RDY)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$14.35

52W Range

$12.90 - $16.89

50D Avg

$15.45

200D Avg

$15.19

Market Cap

$11.93B

Avg Vol (3M)

$799.07K

Beta

0.33

Div Yield

$0.10 (3.35%)

RDY Company Profile


Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NYSE

ADR

Yes

Country

IN

Employees

27,048

IPO Date

Apr 11, 2001

Website

RDY Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMar 24Mar 23Mar 22
Russia CountryINR22.30BINR21.23BINR20.88B
UNITED STATESINR135.56B--
Others Countries CountryINR72.83BINR67.47BINR68.96B
India CountryINR48.47BINR50.50BINR43.99B

Fiscal year ends in Mar 24 | Currency in INR

RDY Financial Summary


Mar 24Mar 23Mar 22
RevenueINR279.16BINR245.88BINR214.39B
Operating IncomeINR66.21BINR96.28BINR40.82B
Net IncomeINR55.68BINR45.07BINR23.57B
EBITDAINR81.05BINR108.78BINR52.64B
Basic EPSINR334.02INR271.47INR142.08
Diluted EPSINR334.02INR270.90INR141.69

Fiscal year ends in Mar 24 | Currency in INR

Latest Earnings Call Transcripts


Q2 25Nov 05, 24 | 1:26 PM
Q4 24May 07, 24 | 2:42 PM
Q3 24Jan 30, 24 | 3:50 PM

Peer Comparison


TickerCompany
SUPNSupernus Pharmaceuticals, Inc.
ITCIIntra-Cellular Therapies, Inc.
ANIPANI Pharmaceuticals, Inc.
PAHCPhibro Animal Health Corporation
SSICSilver Spike Investment Corp.
DCPHDeciphera Pharmaceuticals, Inc.
PBHPrestige Consumer Healthcare Inc.
ALKSAlkermes plc
PCRXPacira BioSciences, Inc.
COLLCollegium Pharmaceutical, Inc.
EVOEvotec SE
EGRXEagle Pharmaceuticals, Inc.